Search Results - "Sala, M.A."

2147 Pathological response as a prognostic factor for disease free survival on colorectal cancer with liver limited disease by Vicente, B.L. San, Nieto, J, Arbide, N, Perez-Hoyos, M.T, Arrazubi, V, Arevalo, A, Arango, J, Zumarraga, A, Fernandez, S, Sala, M.A, Galve, E, Novas, P, Sande, L, Abad, T, Prado, P Martinez del

Get full text

1918 Impact of an osteoporosis unit in the incidence of fractures in early breast cancer patients with aromatase inhibitors by Novas Vidal, P, Fernandez, S, Galve, E, Arrazubi, V, Sala, M.A, Torre, I, Arevalo, A, Arango, J.F, López de San Vicente, B, Pérez, C, Zumárraga, A, Abad, M.T, Garcia, M.L, Marínez, M.P

Get full text

Indications for diagnostic open biopsy of mammographic screen-detected lesions preoperatively diagnosed as fibroadenomas by needle biopsy and their outcomes by Sala, M.A, Dhillon, R, Brookes, D, Lagrange, C, Metcalf, C, Wylie, E

“…Aim To identify the clinical, radiological, and histopathological factors that resulted in a diagnostic open biopsy of mammographic screen-detected lesions…”
Get full text

399 Trend in a Satisfaction Test in Chemotherapy Day Clinic Patients by del Prado, P. Martinez, Utrera, M, Pérez-Hoyos, M.T, Sande, L, Arrazubi, V, Sala, M.A, Gutierrez, M, Antonilli, C, Galve, E

Get full text

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial by Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., Peters, S., Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina, Martinez, Virginia Rodriguez, Roux, Susanne, Sanchez-Hohl, Magdalena, Schneider, Mirjam, Schweri, Robin, Troesch, Sandra, Zigomo, Isabel, Tsourti, Zoi, Zygoura, Panagiota, Kassapian, Marie, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Fernandez, Maria, Pereira, Eva, Simona, Carolina, Tucker, Lisa, Burnes, Jillian, Barrett, Aisling, McGrillen, Meghan, Berset, Catherine, Biaggi, Christine, Reist, Martin, Rentsch, Priska, Cuffe, Sinead, Hashemi, Sayed, Nadal, Ernest, Carcereny, Enric, de Castro, Javier, Sala, Maria Angeles, Reyes, Bernabé, Pulla, Mariano Provencio, Campelo, Rosario Garcia, Massutí, Bartomeu, Garcia, Jose, Dómine, Manuel, Majem, Margarita, Sanchez, Jose Miguel, Britschgi, Christian, Pless, Miklos, Yeo, Chong Ming, Cho, Byoung Chul

“…While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with…”
Get full text

VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial by Soo, R., Han, J-Y., Dimopoulou, G., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabe, R., Coate, L., Provencio, M., Campelo, R. Garcia, Cuffe, S., Hashemi, S., Früh, M., Ruepp, B., Roschitzki-Voser, H., Stahel, R., Peters, S.

Get full text

1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR) by Franco, F.F., Carcereny, E., Castro, R. Lopez, Rodriguez, D., Dols, M.A. Cobo, Caro, R. Bernabe, Cordellat, A. Blasco, Sureda, B. Massuti, Granados, A.L. Ortega, Barco, E. del, Bosch-Barrera, J., Guirado, M., Gonzalez-Larriba, J.L., Vidal, O. Juan, Martinez, J. Mosquera, Rodriguez, J.M. Oramas, Gonzalez, M.A. Sala, Calvo, V., Gonzalez, A. Estival, Provencio, M.

Get full text

1380P Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study) by Franco, F., Costa, E. Carcereny, Rodriguez-Abreu, D., Castro, R. Lopez, Dols, M. Cobo, Guirado, M., Sureda, B. Massuti, Granados, A.L. Ortega, Campelo, R. Garcia, Juan-Vidal, O., Cordellat, A. Blasco, Morillo, E. del Barco, Caro, R. Bernabe, Bosch-Barrera, J., Gonzalez-Larriba, J.L., Gonzalez, M.A. Sala, Perez, J.M. Trigo, Rodriguez, J.M. Oramas, Estival, A., Pulla, M. Provencio

Get full text

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group by Remon, J., Nadal, E., Dómine, M., Ruffinelli, J., García, Y., Pardo, J.C., López, R., Cilleruelo, A., García-Campelo, R., Martín, P., Juan, O., González-Larriba, J.L., Provencio, M., Olmedo, E., Ponce, S., Cumplido, D., Barenys, C., Majem, M., Massutti, B., Rodriguez-Abreu, D., Porta, R., Sala, M.A., Martinez-Kareaga, M., Lianes, P., Reguart, N.

“…•Epidemiological report of mesothelioma treatment patterns and outcomes in Spain.•Despite multimodal intervention, outcomes remain poor (1-year OS of 53.2…”
Get full text

NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) by Guirado, M., Majem, M., Massuti Sureda, B., de las Penas Bataller, R., Ortega Granados, A.L., Isla Casado, M.D., Domine Gomez, M., Marse Fabregat, R., Sala, M.A., Paredes Lario, A., Moran Bueno, M.T., Vazquez Estevez, S., Coves Sarto, J., Gonzalez-Larriba, J.L., Sanchez Torres, J.M., Vicente, D., Farre Bernado, N., Fernandez-Fornos, L., Varcarcel, F., Provencio, M.

Get full text

1461P - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) by Guirado, M., Majem, M., Massuti Sureda, B., de las Penas Bataller, R., Ortega Granados, A.L., Isla Casado, M.D., Domine Gomez, M., Marse Fabregat, R., Sala, M.A., Paredes Lario, A., Moran Bueno, M.T., Vazquez Estevez, S., Coves Sarto, J., Gonzalez-Larriba, J.L., Sanchez Torres, J.M., Vicente, D., Farre Bernado, N., Fernandez-Fornos, L., Varcarcel, F., Provencio, M.

“…CT-RT is the standard treatment for unresectable LA-NSCLC. P plus vinorelbine is widely used. Metronomic CT is a frequent administration of low doses of CT…”
Get full text

1846P - Biomarker testing of lung cancer in Spain by Rodriguez Abreu, D., Guirado, M., Camps Herrero, C.J., Bosch Barrera, J., Bernabé, R., Casal, J., García-Campelo, M.-R., Gonzalez-Larriba, J.L., Massuti Sureda, B., Ortega Granados, A.L., Domine Gomez, M., Sala, M.A., Padilla, A., Del Barco Morillo, E., Oramas Rodriguez, J.M., Blanco Guerrero, R., Aguiar Bujanda, D., López Castro, R., Carcereny Costa, E., Provencio, M.

“…Target therapy guide by biomarkers have become the standard of care for patients with lung cancer (LC). So, identify those molecular alterations is one of the…”
Get full text

Biomarker testing of lung cancer in Spain by Rodriguez Abreu, D., Guirado, M., Camps Herrero, C.J., Bosch Barrera, J., Bernabé, R., Casal, J., García-Campelo, M.-R., Gonzalez-Larriba, J.L., Massuti Sureda, B., Ortega Granados, A.L., Domine Gomez, M., Sala, M.A., Padilla, A., Del Barco Morillo, E., Oramas Rodriguez, J.M., Blanco Guerrero, R., Aguiar Bujanda, D., López Castro, R., Carcereny Costa, E., Provencio, M.

Get full text

1845P - Tobacco use in lung cancer (LC) patients (p) in Spain by Carcereny Costa, E., Guirado, M., Camps Herrero, C.J., Bosch Barrera, J., García-Campelo, M.-R., Ortega Granados, A.L., Gonzalez-Larriba, J.L., De Dios Alvare, N., Domine Gomez, M., Massuti Sureda, B., Sala, M.A., Bernabé, R., Oramas Rodriguez, J.M., del Barco Morillo, E., Padilla, A., Aguiar Bujanda, D., Cerezo Gonzalez, S., Lopez Castro, R., Rodriguez Abreu, D., Provencio, M.

“…Tobacco use, mainly as cigarette smoking, is the leading cause of lung cancer. Eighty-five percent of LC occur in smokers. Understanding the Spanish smoking…”
Get full text

Tobacco use in lung cancer (LC) patients (p) in Spain by Carcereny Costa, E., Guirado, M., Camps Herrero, C.J., Bosch Barrera, J., García-Campelo, M.-R., Ortega Granados, A.L., Gonzalez-Larriba, J.L., De Dios Alvare, N., Domine Gomez, M., Massuti Sureda, B., Sala, M.A., Bernabé, R., Oramas Rodriguez, J.M., del Barco Morillo, E., Padilla, A., Aguiar Bujanda, D., Cerezo Gonzalez, S., Lopez Castro, R., Rodriguez Abreu, D., Provencio, M.

Get full text

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies by MORAN, T, WEI, J, CHAIB, I, YOU, C, MASSUTI, B, SONG, Y, VERGNENEGRE, A, LU, H, LOPEZ-VIVANCO, G, HU, W, ROBINET, G, YAN, J, COBO, M, INSA, A, XU, X, MAJEM, M, CHEN, X, DE LAS PENAS, R, KARACHALIOU, N, SALA, M. A, WU, Q, ISLA, D, ZHOU, Y, QIAN, X, BAIZE, N, ZHANG, F, GARDE, J, GERMONPRE, P, RAUH, S, ALHUSAINI, H, SANCHEZ-RONCO, M, DROZDOWSKYJ, A, SANCHEZ, J. J, CAMPS, C, DOMINE, M, LIU, B, ROSELL, R, ZOU, Z, BOVER, I, WANG, L, PROVENCIO, M, YU, L

“…In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly…”
Get full text

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis by Dafni, U., Soo, R.A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J.-Y., De Castro, J., Coate, L., Früh, M., Hashemi, S.M.S., Nadal, E., Carcereny, E., Sala, M.A., Bernabé, R., Provencio, M., Cuffe, S., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A.

“…The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An…”
Get full text

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies††These studies have previously been presented in part at the ASCO 2013 Annual Meeting, the ESMO-ECCO 2013 Annual Meeting and the IASLC 2013 World Conference on Lung Cancer by Moran, T., Wei, J., Qian, X., Domine, M., Zou, Z., Wang, L., Provencio, M., Yu, L., Song, Y., Vergnenegre, A., Lu, H., Lopez-Vivanco, G., Majem, M., Chen, X., Karachaliou, N., Sala, M.A., Wu, Q., Isla, D., Baize, N., Zhang, F., Garde, J., Germonpre, P., Drozdowskyj, A., Sanchez, J.J., Liu, B., Rosell, R., De Grève, J., Germonpré, P., Chen, H., Chen, X., Gao, Y., Hu, W., Kong, W., Li, L., Li, X., Lu, H., Qian, X., Ren, W., Song, Y., Wei, J., Xu, X., Yang, J., Yang, M., Yue, X., Zhang, J., Zou, Z., Bombaron, P., Dansin, E., Fraboulet, G., Hominal, S., Kahlout, S., Lecaer, H., Lena, H., Monnet, I., Oliviero, G., Schoot, R., Vergnènegre, A., Berchem, G., Al Husaini, H., Aparisi, F., Arriola, E., Bernabé, R., Bosch-Barrera, J., Bover, I., Calvo de Juan, V., Cobo, M., De las Peñas, R., García-Girón, C., García-Gómez, R., Garcia-Sevila, R., Garde, J., Gasco, A., González-Larriba, J.L., Hernando-Polo, S., Jantus, E., Isla, D., Jiménez, B., Lianes, P., López-Martín, A., Macias, J.A., Marti-Ciriquian, J.L., Morán, T., Moreno, M.A., Pallares, C., Porta, R., Reguart, N., Rosell, R., Rosillo, F., Sala, M.A., Sanchez, J.M., Trigo, J.M., Viteri, S., Mate, J.L., Perez-Cano, M., Ramirez, J.L., Sanchez-Rodriguez, B., Ocaña, J., Pereira, E., Shao, J., Sun, X.

“…In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly…”
Get full text

236P Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: An external validation by Pikabea Díaz, F., Galve Calvo, E., Zumarraga, A., Figaredo Bejarano, C., Sala Gonzalez, M.A., Lopez Santillan, M., Lopez De San Vicente, B., Casado, P., Martinez del Prado, M.P.

Get full text

PO-84 Incidence of venous thromboembolism and Khorana score in patients with sarcoma: a retrospective study in a single institution by Figaredo Berjano, C., Zumárraga Cuesta, A., Sala Gónzalez, M.A., López de San Vicente Hernández, A., Nuño Escolástico, M., Galve Calvo, E., Martínez del Prado, M.P.

Get full text